CompletedNCT00253162
Risperidone for mania, then maintenance treatment in bipolarity
About this title
A Study of the Effectiveness and Safety of Risperidone Compared With Placebo in the Treatment of Manic Episodes Associated With Bipolar I Disorder, and the Maintenance of Anti-manic Effectiveness of Risperidone Compared With Haloperidol
Read the official source — NCT00253162This study evaluated the safety and effectiveness of risperidone for people with bipolarity.
Medication studyAges 18+
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of risperidone for people with bipolarity.
Who was this study for?
This study was for people with bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateMarch 2001
- Recruitment status
- Completed
- Enrollment listed in the registry
- 439
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Not clearly listed
- Age range
- Over 18 Years
- Official registry ID
- NCT00253162
- Official title
Show the full official title
The Efficacy And Safety Of Flexible Dose Ranges Of Risperidone Versus Placebo Or Haloperidol In The Treatment Of Manic Episodes Associated With Bipolar I Disorder.
Get this study by email
Recruitment & locations
CompletedLocations not listed
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of risperidone for people with bipolarity.
Who is behind this study?
The study sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including risperidone.
Who was this study for?
This study was for people with bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
"A Randomized, Parallel Group, Open Trial Examining the Safety, Efficacy and Tolerability of Fast Titration, 800mg/day by day 4, of Quetiapine Fumarate Compared to Standard Titration, 400mg/day by ...
Asenapine added to lithium or valproate for mania in bipolar I